Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KADMON HOLDINGS, INC.

(KDMN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
8.76(c) 8.8(c) 8.86(c) 8.89(c) 8.83(c) Last
6 003 356 3 916 581 4 139 963 2 499 113 3 523 557 Volume
+0.34% +0.46% +0.68% +0.34% -0.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5,08 M - -
Net income 2021 -130 M - -
Net Debt 2021 92,6 M - -
P/E ratio 2021 -11,9x
Yield 2021 -
Sales 2022 54,4 M - -
Net income 2022 -116 M - -
Net Debt 2022 52,9 M - -
P/E ratio 2022 -14,0x
Yield 2022 -
Capitalization 1 556 M 1 556 M -
EV / Sales 2021 325x
EV / Sales 2022 29,6x
Nbr of Employees 127
Free-Float 90,8%
More Financials
Company
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
More about the company
Ratings of Kadmon Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about KADMON HOLDINGS, INC.
09/15NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/14KADMON : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price T..
MT
09/13SHAREHOLDER ALERT : Monteverde & Associates PC Announces an Investigation of Kadmon Holdin..
PR
09/10KADMON HOLDINGS INVESTOR ALERT BY TH : Kahn Swick & Foti, LLC Investigates Adequacy of Pri..
BU
09/10KADMON : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9
MT
09/10NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
09/09KADMON : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger
MT
09/09KADMON : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9..
MT
09/09KADMON MERGER INVESTIGATION : Halper Sadeh LLP Announces Investigation Into Whether the Sa..
BU
09/08Sherwin-Williams, PulteGroup fall; Perrigo, Kadmon rise
AQ
09/08ADRs End Lower; Nio, Sanofi Among Companies Actively Trading
DJ
09/08Health Care Flat On Defensive Bias -- Health Care Roundup
DJ
09/08Health Care Stocks Edging Lower Just Ahead of Wednesday Close
MT
09/08Health Care Stocks Fighting to Overcome Market Downdrafts
MT
09/08European Stocks Close Lower Amid Economic Growth Concerns, Rising COVID-19 Cases
MT
More news
News in other languages on KADMON HOLDINGS, INC.
09/08Wall Street termine en repli, le Dow Jones au plus bas en deux semaines
09/08MÄRKTE USA/Wall Street bleibt im Abwärtsmodus
09/08WALL STREET STOCK EXCHANGE : Wall Street lager gesloten
09/08Les actions du secteur de la santé en baisse juste avant la clôture de mercredi
09/08WALL STREET STOCK EXCHANGE : Wall Street koerst af op lager slot
More news
Analyst Recommendations on KADMON HOLDINGS, INC.
More recommendations
Chart KADMON HOLDINGS, INC.
Duration : Period :
Kadmon Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KADMON HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 8,83 $
Average target price 11,58 $
Spread / Average Target 31,2%
EPS Revisions
Managers and Directors
Harlan W. Waksal President, Chief Executive Officer & Director
Steven Meehan Chief Financial Officer & Executive Vice President
Anastasios G. Konidaris Chairman
John L. Ryan Executive Medical Director & Executive VP
Gregory S. Moss Secretary, Chief Compliance Officer & EVP
Sector and Competitors
1st jan.Capi. (M$)
KADMON HOLDINGS, INC.112.77%1 556
CSL LIMITED10.18%103 032
WUXI BIOLOGICS (CAYMAN) INC.14.59%64 160
SAMSUNG BIOLOGICS CO.,LTD.11.62%51 643
BIOGEN INC.19.13%43 475
ALEXION PHARMACEUTICALS, INC.0.00%40 336